NeuroPace Q4 revenue rises

NeuroPace

03/03/2026 21:27

Overview

Medical device firm's Q4 2025 revenue grew 24%, beating analyst expectations

Outlook

NeuroPace expects 2026 revenue growth of 20% to 22% in core RNS revenue

Company anticipates IGE contribution post mid-2026 NAUTILUS PMA-S approval

Result Drivers

RNS SYSTEM SALES - Revenue growth driven by increased sales of RNS System, up 26% from Q4 2024

GROSS MARGIN IMPROVEMENT - Improved gross margin due to positive product mix and manufacturing efficiencies

Company press release: ID:nBwQzbNxa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$26.59 mln
$24.79 mln (8 Analysts)
Q4 EPS
-$0.08
Q4 Net Income
-$2.7 mln
Q4 Gross Profit
$20.58 mln
Q4 Operating Expenses
$22.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Neuropace Inc is $20.00, about 41.3% above its March 2 closing price of $14.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)